Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated KNa1.1 Channel
Lists
Only you see this
Abstract
Gain-of-function (GOF) mutations of the sodium-activated potassium channel K<sub>Na</sub>1.1 (Slack, Slo2.2, or K<sub>Ca</sub>4.1) induce severe, drug-resistant forms of epilepsy in infants and children. Although quinidine has shown promise in treating KCNT1-related epilepsies compared to other drugs, its limited efficacy and substantial side effects necessitate the development of new K<sub>Na</sub>1.1 channel inhibitors. In this study, we developed a novel class of K<sub>Na</sub>1.1 inhibitors using combined silico approaches and structural optimization. Among these inhibitors, compound <b>Z05</b> was identified as a selective potential K<sub>Na</sub>1.1 inhibitor, especially against the hERG channel. Moreover, its binding site and potential counteraction to a GOF mutant Y796H were identified by the mutation studies. Our data also showed that <b>Z05</b> had significant pharmacological profiles, including high brain penetration and moderate oral bioavailability, offering a valuable in vitro tool compound for further drug development in treating KCNT1-related epilepsies.
BibTeX
@article{zheng2024discovery,
author = {Ruqiu Zheng and Zhongtang Li and Qiufeng Wang and Shiqi Liu and Ningfeng Liu and Yiyan Li and Guiwang Zhu and Zhenming Liu and Zhuo Huang and Liangren Zhang},
title = {{Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated K<sub>Na</sub>1.1 Channel}},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01815},
}Loading related content...